| Mon, 18 Mar 2019 19:00:22: | Who'll follow Sanofi CEO Olivier Brandicourt? The company's eyeing candidates now
|
| Mon, 18 Mar 2019 15:33:25: | Gilead's ex-CEO John Milligan picked up $26M pay package on his way out
|
| Mon, 18 Mar 2019 14:16:25: | Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
|
| Mon, 18 Mar 2019 13:54:31: | Spectrum’s Neulasta competitor tripped up by manufacturing issues
|
| Mon, 18 Mar 2019 12:10:25: | ACC: Amarin rolls out more Vascepa heart benefits data to back label expansion
|
| Mon, 18 Mar 2019 12:03:36: | ACC: AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes
|
| Mon, 18 Mar 2019 00:42:05: | Amgen taps comedian Jay Leno for 'cholesterol 911' awareness push
|
| Sun, 17 Mar 2019 15:52:30: | ACC: BMS, Pfizer's Eliquis tops warfarin in high-risk afib subgroup
|
| Fri, 15 Mar 2019 20:49:06: | #FierceMadness is back! Pick your favorite pharma ads in a tournament-style battle royale
|
| Fri, 15 Mar 2019 14:09:23: | Ex-Pfizer CEO Ian Read sees 2018 pay slashed by a third as incentive package plummets
|
| Fri, 15 Mar 2019 13:39:14: | Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China
|
| Fri, 15 Mar 2019 13:30:41: | More trouble for Samsung BioLogics: Prosecutors raid Korea Exchange in IPO probe
|
| Fri, 15 Mar 2019 07:36:52: | FiercePharmaAsia—Gilead loses Riva to Glenmark; Biocon biosim plant; Akili-Shionogi pact
|
| Fri, 15 Mar 2019 06:39:40: | J&J chief Gorsky took a big pay hit in 2018 but still nabbed $20M
|
| Thu, 14 Mar 2019 21:42:12: | Pharma ad police issues 2019's first warning over promotion of unapproved imaging drug
|
| Thu, 14 Mar 2019 18:45:07: | Celgene's Revlimid tops Medicare spending, shares the price-hike title with Pfizer's Lyrica
|
| Thu, 14 Mar 2019 15:20:48: | BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge
|
| Thu, 14 Mar 2019 14:49:39: | FDA drops decisional letter on Lupin sterile drug operations
|
| Thu, 14 Mar 2019 14:20:47: | Johnson & Johnson chalks up another talc loss with $29M mesothelioma verdict
|
| Thu, 14 Mar 2019 14:10:31: | No to Pirro: Allergan pulls ads from Fox show after host questions Muslim rep's loyalty
|
| Thu, 14 Mar 2019 13:34:18: | Merck limits orders for bladder cancer drug as demand outstrips supply
|
| Thu, 14 Mar 2019 12:27:29: | FDA warns Jubilant tablet plant in India for repeat mistakes
|
| Wed, 13 Mar 2019 14:46:10: | Pfizer plant that is closing gets farewell warning letter from FDA
|
| Wed, 13 Mar 2019 13:46:17: | Could a patent dispute over Celgene MS hopeful ozanimod tank the BMS deal?
|
| Wed, 13 Mar 2019 13:41:03: | Lilly CEO David Ricks snags $17.2M pay package for 2018, a 9% hike
|
